Arrowhead Pharmaceuticals

ARWRNASDAQ

TRiM targeted RNAi delivery platform

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-10-02. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-10-02 · archived: kept for reference, not maintained · where each field comes from

RNA interferencecardiometabolicpulmonary

Key figures from SEC filings

We have not parsed a 10-Q or 10-K for ARWR yet, so this page shows no cash, burn or runway figure rather than an estimate. Revenue stage: Pre-revenue.

Upcoming catalysts

Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.

SHASTA-5: Plozasiran in Severe hypertriglyceridemia at high risk of acute pancreatitis — primary completion

2029-03

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

YOSEMITE: Zodasiran in Homozygous familial hypercholesterolemia — primary completion

2027-08-20

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

SHASTA-10: Plozasiran in Hypertriglyceridemia (open-label extension) — primary completion

2028-07

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Pipeline

DrugIndicationPhaseExpected data
Plozasiranfamilial chylomicronemia syndromeApprovedNot disclosed▼
Fazirsiranalpha-1 antitrypsin deficiency-associated liver diseasePhase 2Not disclosed▼
Zodasiranmixed dyslipidemiaPhase 2Not disclosed▼

Analysis

We have not yet written an analysis of Arrowhead Pharmaceuticals that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.
Trade ARWR commission-free on Webullvia Webull · Affiliate

Comparable companies

Alnylam PharmaceuticalsIonis PharmaceuticalsDicerna legacy programs

Sponsored

Get premium ARWR analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Arrowhead Pharmaceuticals has 35 Phase 2 or 3 studies on ClinicalTrials.gov: 13 completed, 11 stopped early, 11 ongoing.

13

Completed

11

Stopped early

11

Ongoing

Stopped early

  • NCT05292950Phase 1/2 · started 2022 · terminated

    ARO-MUC5AC in asthma · n=78

    Reason given: Sponsor business decision

  • GatewayPhase 2 · started 2022 · terminated

    ARO-ANG 3 Injection in homozygous familial hypercholesterolemia · n=18

    Reason given: Business decision, unrelated to safety concerns.

  • NCT04375514Phase 1/2 · started 2020 · terminated

    ARO-ENaC in cystic fibrosis, pulmonary · n=43

    Reason given: Business decision

  • NCT02900183Phase 2 · started 2016 · withdrawn

    ARC-AAT Injection in alpha-1 antitrypsin deficiency · n=0

    Reason given: Company decision to not initiate trial

  • NCT02738008Phase 2 · started 2016 · terminated

    ARC-520 Injection in hepatitis b · n=12

    Reason given: Company decision to discontinue trial

  • MONARCHPhase 2 · started 2015 · terminated

    ARC-520 in hepatitis b · n=79

    Reason given: Company decision to discontinue trial

  • NCT02604212Phase 2 · started 2015 · terminated

    ARC-520 in hepatitis b · n=32

    Reason given: Company decision to discontinue trial

  • NCT02604199Phase 2 · started 2015 · terminated

    ARC-520 Injection in hepatitis b · n=58

    Reason given: Company decision to discontinue trial

  • NCT02452528Phase 2 · started 2015 · terminated

    ARC-520 in chronic hepatitis b · n=4

    Reason given: Company decision to discontinue trial

  • NCT02349126Phase 2 · started 2015 · withdrawn

    ARC-520 Injection in chronic hepatitis b · n=0

    Reason given: Company decision to pursue alternative clinical trial

  • NCT02065336Phase 2 · started 2014 · terminated

    ARC-520 in hepatitis b, chronic · n=58

    Reason given: Company decision to discontinue trial

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.